{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:05:21Z","timestamp":1790352321283,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy requiring multi-modality treatment. Radiotherapy (RT) may improve local control and resection rates, though evidence to support use across various stages of disease is mixed and evolving. This study sought to investigate international practice patterns and provider preferences for the use of radiotherapy in the multidisciplinary management of PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 39-item electronic survey was distributed in 2025 through three sub-specialty organizations to providers who have recently treated PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 176 PDAC providers from six continents completed the survey, with the majority practicing in Europe (\n                      <jats:italic>n<\/jats:italic>\n                      = 76, 43%) and North America (\n                      <jats:italic>n<\/jats:italic>\n                      = 62, 35%). Respondents included mostly surgeons (\n                      <jats:italic>n<\/jats:italic>\n                      = 143, 81%) with 81% (\n                      <jats:italic>n<\/jats:italic>\n                      = 142) practicing in academic centers. Nearly 1 in 5 respondents did not offer or consider any indication for neoadjuvant (\n                      <jats:italic>n<\/jats:italic>\n                      = 32, 19%) or adjuvant (\n                      <jats:italic>n<\/jats:italic>\n                      = 46, 30%) RT. The most commonly cited indication for neoadjuvant RT was for locally advanced disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 88, 52%) and surgically unresectable disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 86, 51%), while the use of adjuvant RT was primarily for positive surgical margins (\n                      <jats:italic>n<\/jats:italic>\n                      = 97, 63%) and positive nodal disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 46, 30%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In an international cohort of surgeons and radiation oncologists, there is substantial variation in perceptions of effectiveness, management preferences, and the propensity to utilize radiotherapy for PDAC. These results underscore the lack of strong evidence to support management, and the need for consensus guidelines and clinical trials to inform best practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01600-0","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:32:34Z","timestamp":1790350354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1007","volume":"57","author":[{"given":"Bradley N.","family":"Reames","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-2604","authenticated-orcid":false,"given":"Aslam","family":"Ejaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"12","key":"1600_CR1","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B","volume":"59","author":"Further evidence of","year":"1987","unstructured":"Further evidence of. effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006\u201310.","journal-title":"Cancer"},{"issue":"6","key":"1600_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","volume":"230","author":"JH Klinkenbijl","year":"1999","unstructured":"Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776\u201382. discussion 82\u2009\u2013\u20094.","journal-title":"Ann Surg"},{"issue":"12","key":"1600_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"9","key":"1600_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263\u201370.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1600_CR5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1600_CR6","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844\u201353.","journal-title":"JAMA"},{"issue":"30","key":"1600_CR7","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO-24-01502","volume":"43","author":"R Fietkau","year":"2025","unstructured":"Fietkau R, Ghadimi M, Grutzmann R, Wittel UA, Jacobasch L, Uhl W, et al. Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial. J Clin Oncol. 2025;43(30):3266\u201378.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1600_CR8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(24)00223-7","volume":"25","author":"YR Lawrence","year":"2024","unstructured":"Lawrence YR, Miszczyk M, Dawson LA, Diaz Pardo DA, Aguiar A, Limon D, et al. Celiac plexus radiosurgery for pain management in advanced cancer: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(8):1070\u20139.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1600_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987\u20131002.","journal-title":"Ann Oncol"},{"issue":"23","key":"1600_CR10","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1200\/JCO.19.00946","volume":"37","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, McKernin SE, Berlin J, Hong TS, Maitra A, Moravek C, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(23):2082\u20138.","journal-title":"J Clin Oncol"},{"key":"1600_CR11","unstructured":"Pancreatic Adenocarcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) [Internet]. 2025; Version 2.2025."},{"issue":"7","key":"1600_CR12","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1245\/s10434-014-4318-x","volume":"22","author":"RW Krell","year":"2015","unstructured":"Krell RW, Reames BN, Hendren S, Frankel TL, Pawlik TM, Chung M, et al. Surgical referral for colorectal liver metastases: a population-based survey. Ann Surg Oncol. 2015;22(7):2179\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1600_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/SLA.0000000000003568","volume":"273","author":"BN Reames","year":"2021","unstructured":"Reames BN, Blair AB, Krell RW, Groot VP, Gemenetzis G, Padussis JC, et al. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. Ann Surg. 2021;273(6):1173\u201381.","journal-title":"Ann Surg"},{"issue":"24","key":"1600_CR14","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1001\/jama.283.24.3217","volume":"283","author":"FJ Fowler Jr","year":"2000","unstructured":"Fowler FJ Jr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283(24):3217\u201322.","journal-title":"JAMA"},{"key":"1600_CR15","doi-asserted-by":"crossref","unstructured":"Abrams RA WKA, Goodman KA, Regine W, Safran A, Berger AC, Guha C, Kachnic LA, Gillin M, Seaward SA, Jing-Ching Wu A, Wu JJ, Aljumaily R, DiPetrillo TA, Geva R, Anne PR, Yannucci J, Liles DK, Moughan J, Crane CH. NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol. 2024;42:4005.","DOI":"10.1200\/JCO.2024.42.16_suppl.4005"},{"issue":"1","key":"1600_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/SLA.0b013e31823d813c","volume":"255","author":"H Takahashi","year":"2012","unstructured":"Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255(1):95\u2013102.","journal-title":"Ann Surg"},{"issue":"11","key":"1600_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.hpb.2017.07.007","volume":"19","author":"T Hackert","year":"2017","unstructured":"Hackert T, Strobel O, Michalski CW, Mihaljevic AL, Mehrabi A, Muller-Stich B, et al. The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford). 2017;19(11):1001\u20137.","journal-title":"HPB (Oxford)"},{"issue":"3","key":"1600_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.prro.2022.01.005","volume":"12","author":"CS Hill","year":"2022","unstructured":"Hill CS, Fu W, Hu C, Sehgal S, Reddy AV, He J, et al. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical Tumor Volume for Pancreatic Ductal Adenocarcinoma of the Head: The Triangle Volume. Pract Radiat Oncol. 2022;12(3):215\u201325.","journal-title":"Pract Radiat Oncol"},{"issue":"10","key":"1600_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","volume":"26","author":"QP Janssen","year":"2025","unstructured":"Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 2025;26(10):1346\u201356.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1600_CR20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/cam4.4527","volume":"11","author":"C Hill","year":"2022","unstructured":"Hill C, Sehgal S, Fu W, Hu C, Reddy A, Thompson E, et al. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. Cancer Med. 2022;11(7):1659\u201368.","journal-title":"Cancer Med"},{"issue":"4","key":"1600_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","volume":"94","author":"S Krishnan","year":"2016","unstructured":"Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1600_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","volume":"7","author":"M Reyngold","year":"2021","unstructured":"Reyngold M, O\u2019Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, Romesser PB, et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol. 2021;7(5):735\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1600_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/pcan.2014.3","volume":"17","author":"SP Kim","year":"2014","unstructured":"Kim SP, Gross CP, Nguyen PL, Smaldone MC, Thompson RH, Shah ND, et al. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(2):163\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"1600_CR24","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ijrobp.2011.01.032","volume":"82","author":"R Jagsi","year":"2012","unstructured":"Jagsi R, Abrahamse P, Morrow M, Hamilton AS, Graff JJ, Katz SJ. Coordination of breast cancer care between radiation oncologists and surgeons: a survey study. Int J Radiat Oncol Biol Phys. 2012;82(5):2072\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1600_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/archsurg.143.4.389","volume":"143","author":"JD Harrison","year":"2008","unstructured":"Harrison JD, Solomon MJ, Young JM, Meagher A, Butow P, Salkeld G, et al. Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg. 2008;143(4):389\u201394.","journal-title":"Arch Surg"},{"issue":"7","key":"1600_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jamasurg.2013.113","volume":"148","author":"N Wasif","year":"2013","unstructured":"Wasif N, Smith CA, Tamurian RM, Christensen SD, Monjazeb AM, Martinez SR, et al. Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg. 2013;148(7):632\u20139.","journal-title":"JAMA Surg"},{"issue":"11","key":"1600_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.gassur.2024.08.013","volume":"28","author":"M Neshan","year":"2024","unstructured":"Neshan M, Padmanaban V, Chick RC, Pawlik TM. Open vs robotic-assisted pancreaticoduodenectomy, cost-effectiveness and long-term oncologic outcomes: a systematic review and meta-analysis. J Gastrointest Surg. 2024;28(11):1933\u201342.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"1600_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12029-025-01177-0","volume":"56","author":"MH Waseem","year":"2025","unstructured":"Waseem MH, Abideen ZU, Durrani R, Dilawar E, Kamran MS, Butt HT, et al. Comparing Operative Outcomes and Resection Quality in Robotic vs Open Pancreaticoduodenectomy: A Meta-analysis of 54,000 Patients. J Gastrointest Cancer. 2025;56(1):57.","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"1600_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","volume":"121","author":"NN Sanford","year":"2025","unstructured":"Sanford NN, Narang AK, Aguilera TA, Bassetti MF, Chuong MD, Erickson BA, et al. NRG Oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2025;121(4):918\u201329.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"1600_CR30","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1200\/JCO.24.00081","volume":"42","author":"EB Ludmir","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol. 2024;42(32):3795\u2013805.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1600_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5889-5","volume":"19","author":"S Heinrich","year":"2019","unstructured":"Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, et al. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19(1):675.","journal-title":"BMC Cancer"},{"issue":"3","key":"1600_CR32","doi-asserted-by":"publisher","first-page":"E69","DOI":"10.1503\/cjs.011213","volume":"57","author":"V Hurdle","year":"2014","unstructured":"Hurdle V, Ouellet JF, Dixon E, Howard TJ, Lillemoe KD, Vollmer CM, et al. Does regional variation impact decision-making in the management and palliation of pancreatic head adenocarcinoma? Results from an international survey. Can J Surg. 2014;57(3):E69\u201374.","journal-title":"Can J Surg"},{"issue":"4","key":"1600_CR33","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/SLA.0000000000000248","volume":"259","author":"BN Reames","year":"2014","unstructured":"Reames BN, Shubeck SP, Birkmeyer JD. Strategies for reducing regional variation in the use of surgery: a systematic review. Ann Surg. 2014;259(4):616\u201327.","journal-title":"Ann Surg"},{"issue":"9898","key":"1600_CR34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(13)61215-5","volume":"382","author":"JD Birkmeyer","year":"2013","unstructured":"Birkmeyer JD, Reames BN, McCulloch P, Carr AJ, Campbell WB, Wennberg JE. Understanding of regional variation in the use of surgery. Lancet. 2013;382(9898):1121\u20139.","journal-title":"Lancet"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01600-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:32:36Z","timestamp":1790350356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01600-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University of Illinois at Chicago (protocol code 2024\u2009\u2212\u20091167 approved on November 15, 2024).","order":1,"name":"Ethics","label":"Institutional Review Board","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}